U.S. business groups criticized the Indian Supreme Court's landmark drug patent ruling, saying it will harm global pharmaceutical innovation. "We recognize the importance of generics to the contribution of health once patents expire, but ... for India to become the innovation nation of the 21st century, it should reward and encourage innovation," U.S.-India Business Council President Ron Somers said. PhRMA spokesman Mark Grayson expressed concerns that the ruling would slow market entry of critically needed new treatments, as development costs sometimes exceed $1 billion.

Related Summaries